The appraisal for hybrid closed loop systems as an option for managing blood glucose levels in type 1 diabetes was discussed by the diagnostics advisory committee on 24 May 2023. The committee has reached a conclusion to recommend hybrid closed loop systems as an option for managing blood glucose levels in type 1 diabetes.
Companies will now be invited to engage with NHS England (NHSE) on a commercial exercise to offer cost-effective value propositions for HCL systems.
NHSE have asked NHS Supply Chain to issue a Request for Information (RFI) to provide an opportunity to test scenarios for roll out of HCL technology to patients, including the price and requirements for the future procurement.
To support this exercise there will be a number of supplier engagement opportunities planned over the summer. Further details will be published on the NHS Supply Chain website in the coming weeks.
The commercial exercise will last a maximum of 16 weeks and is expected to conclude by 13 October 2023.
NHSE have also indicated their intention to request a variation to the funding requirement for this technology and, if accepted by NICE, consultees and commentators will be given the opportunity to participate in a consultation on this during the 16-week period. Consultees and commentators will be alerted to this when the consultation begins.
The detail of the committee discussion and draft recommendations will be provided in a Final Draft Guidance document following the commercial exercise. We anticipate this will be sent to stakeholders in the week commencing 16 October 2023 and will be published on the NICE website seven days later.